Regeneron's Lynozyfic Trial Shows Promising Results in AL Amyloidosis
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: NASDAQ.COM
- Trial Results: Regeneron's Phase 1/2 LINKER-AL2 trial demonstrated that all 20 patients treated with Lynozyfic achieved a hematologic response, indicating significant efficacy in treating relapsed or refractory systemic AL amyloidosis.
- Dose Response Analysis: Among the 7 patients receiving the 80 mg dose, all achieved a very good partial response or better, including 5 complete responses, while all 13 patients in the 240 mg group achieved complete responses, highlighting a positive correlation between dosage and efficacy.
- Rapid and Effective Response: Free light chain levels normalized by day 15, with a median time to complete response of 47 days, indicating that Lynozyfic quickly eliminates harmful protein-producing plasma cells, enhancing treatment expectations for patients.
- Organ Response Improvement: Among evaluable patients, 73% showed renal improvement and 50% showed cardiac improvement, with no major organ deterioration reported during the study, demonstrating both the safety and efficacy of Lynozyfic.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy REGN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on REGN
Wall Street analysts forecast REGN stock price to rise
22 Analyst Rating
16 Buy
6 Hold
0 Sell
Moderate Buy
Current: 649.760
Low
637.00
Averages
808.50
High
1057
Current: 649.760
Low
637.00
Averages
808.50
High
1057
About REGN
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Lynozyfic, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Regeneron Reports Positive LINKER-AL2 Trial Results for Lynozyfic
- Clinical Trial Results: In the LINKER-AL2 trial, Lynozyfic (linvoseltamab) achieved a nearly 100% hematologic complete response (CR) in patients with systemic AL amyloidosis who had received at least one prior therapy, demonstrating its remarkable efficacy compared to the standard-of-care.
- Organ Function Improvement: Despite the short follow-up, 73% of patients showed improved renal function and 50% showed improved cardiac function, indicating Lynozyfic's potential to enhance vital organ performance and provide new hope for patients facing life-threatening conditions.
- Safety Assessment: Among 20 patients treated, Lynozyfic exhibited no dose-limiting toxicities, although all experienced at least one treatment-emergent adverse event, with 65% being grade 3 or higher, highlighting the need for careful monitoring of safety profiles.
- Future Research Directions: The ongoing Phase 2 portion of the LINKER-AL2 trial aims to further validate the efficacy and safety of Lynozyfic, potentially offering new treatment options for patients with systemic AL amyloidosis who currently lack effective therapies.
See More
Regeneron's Lynozyfic Trial Shows Promising Results in AL Amyloidosis
- Trial Results: Regeneron's Phase 1/2 LINKER-AL2 trial demonstrated that all 20 patients treated with Lynozyfic achieved a hematologic response, indicating significant efficacy in treating relapsed or refractory systemic AL amyloidosis.
- Dose Response Analysis: Among the 7 patients receiving the 80 mg dose, all achieved a very good partial response or better, including 5 complete responses, while all 13 patients in the 240 mg group achieved complete responses, highlighting a positive correlation between dosage and efficacy.
- Rapid and Effective Response: Free light chain levels normalized by day 15, with a median time to complete response of 47 days, indicating that Lynozyfic quickly eliminates harmful protein-producing plasma cells, enhancing treatment expectations for patients.
- Organ Response Improvement: Among evaluable patients, 73% showed renal improvement and 50% showed cardiac improvement, with no major organ deterioration reported during the study, demonstrating both the safety and efficacy of Lynozyfic.
See More
Pomerantz LLP Investigates Regeneron for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating whether Regeneron Pharmaceuticals and its executives have engaged in securities fraud or other unlawful business practices, which could undermine investor confidence and lead to legal repercussions.
- Disappointing Clinical Trial Results: On May 15, 2026, Regeneron disclosed that its Phase 3 trial of the LAG-3 inhibitor fianlimab combined with the PD-1 inhibitor cemiplimab failed to achieve statistical significance for the primary endpoint of progression-free survival, potentially impacting future drug development and market performance.
- Significant Stock Price Drop: Following the trial results announcement, Regeneron's stock price fell by $68.57, or 9.82%, closing at $629.68 on May 16, 2026, reflecting market concerns about the company's future prospects.
- Potential Legal Consequences: As a prominent securities litigation firm, Pomerantz LLP may provide legal support to affected investors, further exacerbating the legal and financial risks faced by Regeneron.
See More
Parabilis Medicines Files for IPO After $2.3B Deal with Regeneron
- Research Collaboration: Parabilis Medicines has entered into a research agreement with Regeneron valued at up to $2.3 billion, which includes $125 million upfront and potential milestone payments, indicating strong market confidence in the Helicons treatment class.
- IPO Filing Submitted: The company has filed an S-1 with the SEC, aiming to list on Nasdaq under the ticker PBLS, marking a significant step in its financing and market expansion strategy.
- Clear Use of Proceeds: Parabilis disclosed that net proceeds from the IPO will be used to advance its lead product candidate, zolucatetide, which is expected to enter a global registrational Phase 3 trial in H1 2027 targeting patients with rare soft tissue tumors.
- Broad Market Prospects: By collaborating with Regeneron, Parabilis not only secures funding but also leverages Regeneron's VelocImmune technology, enhancing its competitive position in the biopharmaceutical sector and driving long-term growth for the company.
See More
ETF Analysis: FDG Implies 19.53% Upside Potential
- FDG ETF Potential: The American Century Focused Dynamic Growth ETF (FDG) has an implied analyst target price of $161.52 per unit, while trading at $135.13, indicating a 19.53% upside potential, reflecting market optimism about the ETF's future performance.
- Regeneron Upside: Regeneron Pharmaceuticals (REGN) trades at $630.30, with an analyst target price of $876.53, suggesting a potential upside of 39.07%, showcasing strong analyst confidence in its future performance.
- Robinhood Market Expectations: Robinhood Markets (HOOD) is currently priced at $74.16, with an analyst target of $99.86, indicating a 34.66% upside potential, reflecting optimistic market expectations regarding its business growth.
- MPWR Target Analysis: Monolithic Power Systems (MPWR) trades at $1468.11, with an analyst target of $1820.00, suggesting a potential upside of 23.97%, which may attract investor interest in its future growth potential.
See More
Analysis of IBB ETF Trading Dynamics
- Price Fluctuation Analysis: IBB ETF's 52-week low is $119.78 per share, with a high of $179.64, and a current trading price of $163.87, indicating relative stability in a volatile market that may attract investor interest.
- Technical Analysis Tool: Comparing the current share price to the 200-day moving average can provide valuable technical insights for investors, aiding in better market trend assessment and timing for investments.
- ETF Unit Trading Mechanism: ETFs trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on investor demand, impacting the liquidity and market performance of the ETF.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in ETF shares outstanding focuses on those experiencing notable inflows (new units created) or outflows (old units destroyed), as these liquidity shifts can affect the performance of individual stocks held within the ETF.
See More
Regeneron Reports Positive LINKER-AL2 Trial Results for Lynozyfic
- Clinical Trial Results: In the LINKER-AL2 trial, Lynozyfic (linvoseltamab) achieved a nearly 100% hematologic complete response (CR) in patients with systemic AL amyloidosis who had received at least one prior therapy, demonstrating its remarkable efficacy compared to the standard-of-care.
- Organ Function Improvement: Despite the short follow-up, 73% of patients showed improved renal function and 50% showed improved cardiac function, indicating Lynozyfic's potential to enhance vital organ performance and provide new hope for patients facing life-threatening conditions.
- Safety Assessment: Among 20 patients treated, Lynozyfic exhibited no dose-limiting toxicities, although all experienced at least one treatment-emergent adverse event, with 65% being grade 3 or higher, highlighting the need for careful monitoring of safety profiles.
- Future Research Directions: The ongoing Phase 2 portion of the LINKER-AL2 trial aims to further validate the efficacy and safety of Lynozyfic, potentially offering new treatment options for patients with systemic AL amyloidosis who currently lack effective therapies.
See More
Regeneron's Lynozyfic Trial Shows Promising Results in AL Amyloidosis
- Trial Results: Regeneron's Phase 1/2 LINKER-AL2 trial demonstrated that all 20 patients treated with Lynozyfic achieved a hematologic response, indicating significant efficacy in treating relapsed or refractory systemic AL amyloidosis.
- Dose Response Analysis: Among the 7 patients receiving the 80 mg dose, all achieved a very good partial response or better, including 5 complete responses, while all 13 patients in the 240 mg group achieved complete responses, highlighting a positive correlation between dosage and efficacy.
- Rapid and Effective Response: Free light chain levels normalized by day 15, with a median time to complete response of 47 days, indicating that Lynozyfic quickly eliminates harmful protein-producing plasma cells, enhancing treatment expectations for patients.
- Organ Response Improvement: Among evaluable patients, 73% showed renal improvement and 50% showed cardiac improvement, with no major organ deterioration reported during the study, demonstrating both the safety and efficacy of Lynozyfic.
See More
Pomerantz LLP Investigates Regeneron for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating whether Regeneron Pharmaceuticals and its executives have engaged in securities fraud or other unlawful business practices, which could undermine investor confidence and lead to legal repercussions.
- Disappointing Clinical Trial Results: On May 15, 2026, Regeneron disclosed that its Phase 3 trial of the LAG-3 inhibitor fianlimab combined with the PD-1 inhibitor cemiplimab failed to achieve statistical significance for the primary endpoint of progression-free survival, potentially impacting future drug development and market performance.
- Significant Stock Price Drop: Following the trial results announcement, Regeneron's stock price fell by $68.57, or 9.82%, closing at $629.68 on May 16, 2026, reflecting market concerns about the company's future prospects.
- Potential Legal Consequences: As a prominent securities litigation firm, Pomerantz LLP may provide legal support to affected investors, further exacerbating the legal and financial risks faced by Regeneron.
See More
Parabilis Medicines Files for IPO After $2.3B Deal with Regeneron
- Research Collaboration: Parabilis Medicines has entered into a research agreement with Regeneron valued at up to $2.3 billion, which includes $125 million upfront and potential milestone payments, indicating strong market confidence in the Helicons treatment class.
- IPO Filing Submitted: The company has filed an S-1 with the SEC, aiming to list on Nasdaq under the ticker PBLS, marking a significant step in its financing and market expansion strategy.
- Clear Use of Proceeds: Parabilis disclosed that net proceeds from the IPO will be used to advance its lead product candidate, zolucatetide, which is expected to enter a global registrational Phase 3 trial in H1 2027 targeting patients with rare soft tissue tumors.
- Broad Market Prospects: By collaborating with Regeneron, Parabilis not only secures funding but also leverages Regeneron's VelocImmune technology, enhancing its competitive position in the biopharmaceutical sector and driving long-term growth for the company.
See More
ETF Analysis: FDG Implies 19.53% Upside Potential
- FDG ETF Potential: The American Century Focused Dynamic Growth ETF (FDG) has an implied analyst target price of $161.52 per unit, while trading at $135.13, indicating a 19.53% upside potential, reflecting market optimism about the ETF's future performance.
- Regeneron Upside: Regeneron Pharmaceuticals (REGN) trades at $630.30, with an analyst target price of $876.53, suggesting a potential upside of 39.07%, showcasing strong analyst confidence in its future performance.
- Robinhood Market Expectations: Robinhood Markets (HOOD) is currently priced at $74.16, with an analyst target of $99.86, indicating a 34.66% upside potential, reflecting optimistic market expectations regarding its business growth.
- MPWR Target Analysis: Monolithic Power Systems (MPWR) trades at $1468.11, with an analyst target of $1820.00, suggesting a potential upside of 23.97%, which may attract investor interest in its future growth potential.
See More
Analysis of IBB ETF Trading Dynamics
- Price Fluctuation Analysis: IBB ETF's 52-week low is $119.78 per share, with a high of $179.64, and a current trading price of $163.87, indicating relative stability in a volatile market that may attract investor interest.
- Technical Analysis Tool: Comparing the current share price to the 200-day moving average can provide valuable technical insights for investors, aiding in better market trend assessment and timing for investments.
- ETF Unit Trading Mechanism: ETFs trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on investor demand, impacting the liquidity and market performance of the ETF.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in ETF shares outstanding focuses on those experiencing notable inflows (new units created) or outflows (old units destroyed), as these liquidity shifts can affect the performance of individual stocks held within the ETF.
See More
